Testing effectiveness (Phase 2)Not Yet RecruitingNCT07623642
What this trial is testing
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
Who this might be right for
Uterine Cervical NeoplasmsTriple Negative Breast NeoplasmsProstatic Neoplasms+8 more
GV20 Therapeutics 227